Rhumbline Advisers Innate Pharma Sa Call Options Transaction History
Rhumbline Advisers
- $104 Billion
- Q1 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding IPHA
# of Institutions
10Shares Held
97.2KCall Options Held
0Put Options Held
0-
Morgan Stanley New York, NY43.5KShares$77,0370.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il24.3KShares$42,9520.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny15.3KShares$27,1270.0% of portfolio
-
Ubs Group Ag9KShares$15,9310.0% of portfolio
-
Gamma Investing LLC Foster City, CA3.46KShares$6,1170.0% of portfolio
About Innate Pharma SA
- Ticker IPHA
- Exchange OTC
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 79,893,000
- Market Cap $141M
- Description
- Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and periphera...